MB
ANL

MPM BioImpact’s Adlai Nortye ANL Stock Holding History

MPM BioImpact’s Portfolio ANL Stock Details ANL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3M Buy
+1,936,291
New +$23.6M 1.36% 27

Other funds holding ANL

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return

MPM BioImpact's ANL Position: Q2 2026 in Review

MPM BioImpact opened a new position in Adlai Nortye (ANL) in Q2 2026: 1,936,291 shares worth $22.3M. The stake represents 1.36% of the portfolio and ranks #27 among its holdings.

35 funds tracked by Wall St. Rank hold ANL as of Q2 2026.

  • MPM BioImpact held 1,936,291 shares of Adlai Nortye worth $22.3M as of Q2 2026.
  • Adlai Nortye was a new MPM BioImpact position in Q2 2026.
  • Adlai Nortye made up 1.36% of MPM BioImpact's portfolio in Q2 2026, its #27 holding.
  • 35 funds tracked by Wall St. Rank held Adlai Nortye as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.